Fruquintinib
Phase 1Completed 0 watching 0 views this week๐ค Quiet
28
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout Fruquintinib
Fruquintinib is a phase 1 stage product being developed by HUTCHMED for Tumor. The current trial status is completed. This product is registered under clinical trial identifier NCT01645215. Target conditions include Tumor.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05216354 | Phase 1 | Completed |
| NCT05216367 | Phase 1 | Completed |
| NCT03684967 | Phase 2 | Withdrawn |
| NCT02689752 | Phase 1 | Completed |
| NCT01975077 | Phase 1/2 | Completed |
| NCT01955304 | Phase 1 | Completed |
| NCT01645215 | Phase 1 | Completed |
Competing Products
20 competing products in Tumor